Falls Sie weiterhin Auto-Updates beziehen möchten, klicken Sie bitte auf Ja.
Eröffnen Sie jetzt Ihr Depot und Bankkonto bei
cash – banking by bank zweiplus in 5 Schritten.Trading-Konto eröffnen
Auf der Internetseite gibt es eine neue Pressemitteilung zu Imperia. Stieg der Kurs gestern deshalb so stark?
Der Kommentar von dangermouse wurde ignoriert. Um die Kommentare von dangermouse wieder zu sehen, klicken Sie folgenden Link:
News zu New Venturetec sind leider spärlich, das Kursfeuerwerk von gestern war aber von kurzer Dauer, aktuell ist sie 10% im minus.
Der Kommentar von Hans wurde ignoriert. Um die Kommentare von Hans wieder zu sehen, klicken Sie folgenden Link:
Google Alert for: osiris therapeutics
Osteoarthritis patients don't need to come to grinding halt
USA Today - USA
... Vangsness and his colleagues are testing a stem cell therapy developed by Osiris Therapeutics. The Baltimore company has developed ...
By Kathleen Fackelmann, USA TODAY
Mercedes Levis took a chance last month and got the latest upgrade on the artificial knee, one designed for women. The 76-year-old Birchrunville, Pa., woman figured the next generation in knee implants would let her live her life again — without disabling pain.
Levis is one of about 400,000 Americans who will get an artificial knee this year, a number that will explode in the next 25 years as aging Americans start to develop osteoarthritis in record numbers. Experts like Steven Kurtz of Exponent Inc., a technology consulting firm, predict that by the year 2030, nearly 3.5 million Americans will need an artificial knee.
"We're living longer and, as a consequence of living longer, our joints begin to give way," says Christopher Buckland-Wright, an arthritis researcher at the King's College in London.
Researchers today are searching for new drugs that would go beyond treating the symptoms to push back the disease itself. They also are looking at futuristic techniques like stem cell therapy that promise to repair long-term damage. Meanwhile, companies are improving artificial joints to give people like Levis a better quality of life.
Stem cells offer promise
Drugs available today can ease symptoms of osteoarthritis — the most common type of arthritis — but don't halt the underlying destruction of the cartilage, the slippery tissue that cushions the joints, says Debra McCoy, a vice president for research at the Atlanta-based Arthritis Foundation.
That's in sharp contrast to the treatment for rheumatoid arthritis: Drugs called biologic response modifiers can, in many cases, stop the ongoing damage to the joints caused by an autoimmune attack.
But if research by Buckland-Wright and others pans out, Americans at risk of getting osteoarthritis might be able to count on new techniques or drugs that would push back the disease or even repair existing damage.
Osteoarthritis not only destroys cartilage, it also weakens the bones that form the joint. Buckland-Wright and his colleagues now have evidence that risedronate, an osteoporosis drug, might help slow the progression of osteoarthritis. His team gave the drug to people with severe osteoarthritis of the knee for two years.
"The drug stopped bone loss dead," Buckland-Wright says. A higher dose seemed to actually restore some bone in the knee joint, he says. His team presented the research in November at the American College of Rheumatology meeting held in San Diego.
But additional studies must prove that risedronate or similar drugs can slow the disease, cautions Roy Fleischmann, a rheumatologist at the University of Texas Southwestern Medical Center in Dallas. "There isn't enough evidence to recommend that people use (risedronate) for osteoarthritis yet," he says.
Stem cell therapy — a technique that relies on the idea that stem cells can be prompted to turn into cartilage cells that will grow and repair damage — is another possible avenue for future treatment. Johns Hopkins researcher Jennifer Elisseeff has used the method in rats, finding that stem cells can fill in holes in the cartilage.
"These cells have the amazing ability to repair parts of the body," says Thomas Vangsness, an orthopedic surgeon at the University of Southern California in Los Angeles.
Vangsness and his colleagues are testing a stem cell therapy developed by Osiris Therapeutics. The Baltimore company has developed a solution of stem cells taken from a single adult donor. Vangsness and his colleagues injected the stem cell solution into the knees of 55 patients with a torn meniscus, cartilage-like tissue in the knee. They're hoping the stem cells will turn into cartilage cells and repair the injury, but the data are just now being analyzed, Vangsness says.
He hopes to have some answers in the fall. "If it does work — that would be a huge deal," Vangsness says. But can stem cells go beyond treating simple injuries and stop an ongoing disease process — one that constantly grinds up cartilage?
Fleischmann calls that concept "pie in the sky" but says that years from now doctors might have injectable stem cell therapy or some other technique that could hold the line on osteoporosis. "If we could regrow cartilage," Fleischmann says, "that would be the holy grail."
Better artificial joints available
But patients like Levis can't wait for stem cell therapy or any other futuristic techniques. Levis says osteoarthritis had destroyed most of the cartilage in her knees, making it painful to walk even short distances. That's why she opted for the new knee by Zimmer. The company just received Food and Drug Administration approval to market the knee, which is shaped to fit the female knee, says Robert Booth, the orthopedic surgeon at Pennsylvania Hospital who helped develop the device.
The Zimmer knee joins a long list of upgrades to artificial joints, improvements that give people like Levis the assurance that they have an artificial joint that will move more like their own knee did when it was healthy. Levis hasn't gotten there yet. She's still has some pain.
But she had the surgery to replace both knees last month and, despite a little pain, she's still out gardening and taking short walks. She's hoping that by the end of the summer she'll be pain-free and able to reclaim her life. "I'm looking forward to walking a couple of miles a day with my dogs."
Wieviel bringt dieser Börsengang NEV ein :?:
Osiris Therapeutics will hold an IPO Road Show Presentation on Wednesday, July 19, 2006, from 12.00 to 13.30 at the Park Hyatt, Beethovenstrasse 21, 8022 Zurich.
If you wish to participate on this presentation please kindly replay to this email.
If you wish a one-on-one meeting with the management of Osiris please contact us.
Friedli Corporate Finance
Tel: +41 44 283 2900
Fax: +41 44 283 2901
Der Kommentar von Kapitalist wurde ignoriert. Um die Kommentare von Kapitalist wieder zu sehen, klicken Sie folgenden Link:
23,6 % von New Venturetec beträgt die Beteiligung von Osiris und New Venturetec ist damit an 14,6% von Osiris beteiligt. Die gesamte Beteiligung von NEV steht mit 43,2 Millionen US$ in den Büchern von NEV. Ein Börsengang von Osiris bringt also sicher einen grösseren Betrag in die Kasse von New Venturetec. Die Aktie von New Venturetec wird hoffentlich bald abheben.
Besser reich und gesund als arm und krank!
der verkaufsprospekt von osiris ist draußen:
die jungs wollen 3,5 millionen shares zwischen 11 und 13 $ raushauen, außerdem gibts nen greenshoe von 500k.
die investmentbanken würde der company bei erfolgreichem ipo damit eine Market Cap von 300 bis 380 millionen $ zugestehen.
23% davon gehört New Venturetec, macht immerhin 69 - 88 Mio US$
Aktuell steht die Beteiligung von Osiris mit 43,2 Mio. US$ zu Buche, je nach dem würde der innere Wert von NEV also um 26 - 45 Mio US$ zunehmen. Der gesamte innere Wert von New Venturtec beträgt aktuell 118,5 Mio., d.h. New Venturetec wird zwischen 20% und gegen 40% des inneren Wertes zulegen. Im selben Ausmass sollte natürlich auch der Aktienkurs steigen!
Wer noch keine hat, sollte jetzt noch schnell zugreifen.
Mit Deiner Rechnerei hast Du mich kurz in die Irre geführt Hans, der Kursanstieg resp. der innere Wert von New Venturetec wird so gegen 140% betragen! Da kann man bei einen Engagement auf dem aktuellen Kurs aber massive Gewinne einfahren!
New Venturetec hält 17 Mio. Aktien von Osiris. Da die Aktien an der NASDAQ gelistet werden und jetzt zu 11 - 13 Dollar angeboten werden, erhöht sich der innere Wert von NEV um diesen Preis, d. h. bei einem Durchschnittskurs von angenommen 12 Dollar ist diese Beteiligung mit dem Börsengang plötzlich 204 Millionen Dollar wert, bei höherem Aktienkurs natürlich noch mehr! Aktuell wird die Beteiligung an Osiris mit 43,2 Millionen Dollar geführt, der Gesamtwert des Portfolios wird mit 118 Millionen Dollar gewertet. Nach dem Börsengang von Osiris wird das Gesamtportfolio von New Venturetec aber einen Gesamtwert von rund 279 Millionen Dollar haben! Das heisst der innere Wert von New Venturetec wird um rund 140% ansteigen! Logischerweise sollte der Aktienkurs von New Venturetec dann etwa um den selben Wert ansteigen! :roll: :roll: :roll: :roll: :oops:
Bei New Venturetec sind 5 Millionen Aktien ausstehend, pro Aktie würde das einen inneren Wert von gut 55 Dollar ergeben oder rund Fr. 70.- pro Titel! Aktuell wird der innere Wert pro Aktie aber bloss mit rund Fr. 30.- angegeben. Mit Osiris ist ja der Peter Friedli buchstäblich auf eine Goldader gestossen!
Siehe unter Net Asset Value Report: Osiris
..gerechnet habe ich nur überschlagsmässig, ohne Rücksicht auf die Buchführung von NEV
..könnte so stimmen, denn aktuell wird gerade versucht, den NEV-Kurs zu dumpen um günstiger an die Ware zu kommen... :x
...wann ist denn der IPO terminlich angesetzt, habe nix gefunden :?:
IPO soll bis 10.08.2006 erfolgen, sofern alles nach Plan verläuft
Gemäss Prospekt gibts jetzt einen 1 für 4 reverse split, das enspricht bei ursprünglich $12 genau $3, so ist es bei New Venturetec bereits bewertet.
Hier noch ein abgekupferter Link zu Stammzellen Research
Wikipedia, soeben nachgetragen : http://de.wikipedia.org/wiki/Osiris
Muss sagen, Osiris Chairman Peter Friedli macht da ganze Arbeit, direkt an die Nasdaq - das tönt cool
IPO Spotlight: Osiris Therapeutics
Friday July 28, 4:11 pm ET
By Wallace Witkowski, AP Business Writer
Osiris Therapeutics Plans Public Debut Into Volatile Stem Cell Biotech Market
NEW YORK (AP) -- Amid the recent controversy surrounding stem cell research, Osiris Therapeutics Inc. plans to join the small cadre of publicly traded biotech companies developing treatments using the technology, setting itself apart as the only company with a stem cell treatment on the U.S. market.
However, the Baltimore-based biotech company enters a challenging market for stem cell companies, in which stock prices tend to get worse before they get better.
Last week, Osiris said in a filing with the Securities and Exchange Commission it will sell 3.5 million shares at $11 to $13 apiece in its initial public offering, slated for July 31. An additional 525,000 shares will be made available to underwriters for overallotments. Jefferies & Co. is the lead bookrunning manager and Lazard Capital Markets is acting as co-lead manager.
In the company\'s original May registration statement, Osiris filed to sell up to $80 million of its shares. Under the amended registration, the company would only sell $38.5 million to $45.5 million worth of shares.
So far this year, eight biotech companies have launched IPOs, and seven others filed proposals.
Rich Peterson, a research analyst with Thomson Financial, said biotech stocks that have debuted this year are off an average of 9 percent, while stocks that debuted last year are off an average of 3 percent from their initial price.
"In general biotech IPOs are hard pressed," said Peterson in an interview. "It\'s the nature of business: they generally don\'t have established products, and are hoping to hit it big."
On the whole, Peterson said the year has been pretty flat for IPOs, with notable successes like J. Crew and Chipolte balanced by disappointments like Vonage.
In its latest filing, Osiris sets itself apart from competitors by saying it sells the only commercially available product in the United States containing viable stem cells. The product, Osteocel, is used to regenerate bone. Launched in July 2005, Osiris booked Osteocel sales of $957,000 in 2005, and $1.1 million in the quarter ended March 31. Osiris uses stem cells harvested from adult bone marrow.
The business plans to develop products that prevent the rejection of bone marrow transplants in cancer patients, heal heart tissue after a heart attack, and regenerate tissue following knee injuries to prevent arthritis. The company has a strategic alliance with medical device maker Boston Scientific Corp. for the heart application.
Founded in 1992, the company said in its filing it has spent $147.7 million to date and expects losses to continue "for at least the next several years." In 2005, the company posted a loss of $20 million, and recorded a loss of $5.1 million in the quarter ended March 31.
Currently, Osiris Chairman Peter Friedli owns 54 percent of shares and Swiss investment firm Venturetec Inc., where Friedli acts as president, owns 13 percent. After the offering, Friedli will own 48 percent of the company, and Venturetec will hold 12 percent of the roughly 27 million outstanding shares.
Osiris plans to use proceeds for research and development, general corporate purposes, and possibly to prepay principal and interest on a promissory note.
The company has three products in development: Prochymal for bone marrow transplant use, Provacel for repairing heart tissue, and Chondrogen for regenerating knee cartilage.
Prochymal is the farthest along, and is about to enter late-stage clinical trials. Prochymal is designated an orphan drug with a fast-track review by the Food and Drug Administration, meaning that the company can submit data as it becomes available -- rather than having to wait to submit it all at once -- and that the drug will receive seven years of marketing exclusivity if approved.
In April, the company completed enrollment for an early-to-mid-stage clinical trial for Chondrogen, and an early-stage clinical trial for Provacel.
Compared with those of their larger biotech counterparts, stock prices of smaller stem cell technology companies have steadily drifted toward 52-week lows in the past year. Publicly traded companies include StemCells Inc., Aastrom Biosciences Inc., ViaCell Inc. and Geron Corp., the only publicly traded company to use embryonic stem cells in research.
In comparison, the American Stock Exchange\'s Biotechnology Index, which follows 20 biotech companies, is up about 4 percent from a year ago.
Stem cells extracted from embryos are controversial because the embryos are destroyed in the process. Last week, President Bush used the first veto of his presidency to block a bill to allow more federal funding for embryonic stem cell research. Congress did not produce enough votes to overturn the veto.
Osiris plans to trade on the Nasdaq under the ticker symbol "OSIR."
OSIR wird heute erstmals gehandelt - NASDAQ
Osiris Announces Pricing of Its Initial Public Offering
August 4, 2006 – Baltimore, Maryland - Osiris Therapeutics, Inc. announced today the pricing of its initial public offering of 3,500,000 shares of its common stock at a price of $11.00 per share. All of the shares are being sold by the Company. Up to an additional 525,000 shares have been made available to the underwriters to cover over-allotments, if any. Osiris’ common stock is expected to begin trading on The NASDAQ Global Market on Friday August 4, 2006 under the symbol "OSIR."
The shares are being offered by an underwriting syndicate led by Jefferies and Company acting as the bookrunning manager with Lazard Capital Markets and Leerink Swann and Company acting as the Co-Lead and Co-Manager, respectively. This offering will be made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from Jefferies and Company, 520 Madison Avenue, 12th Floor, New York, NY 10022 or by fax request at (212) 284-2208.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 3, 2006. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction or state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or state.
About Osiris Therapeutics
Osiris Therapeutics, Inc. (NASDAQ:OSIR) is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel® for regenerating bone in orthopedic indications. Prochymal™ is entering Phase III clinical trials and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. The Company’s pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen™ for regenerating cartilage in the knee, and Provacel™, for repairing heart tissue following a heart attack. Osiris is a fully integrated company, having developed stem cell capabilities in research and development, manufacturing, marketing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company’s technology in the United States and a number of foreign countries including 45 U.S. and 153 foreign patents owned or licensed.
For additional information, please contact Lisa Rodemann at 410.522.5005, extension 610.
Schlusskurs: $11 (wie Eröffnung)
Das ist aber ein Kurs am unteren Ende der Angebotsbreite, die wurden doch für 11 -13 $ angeboten. Wie ist das Kürzel das du eingegeben hast? Wenn ich OSIR eingebe kommt nur ein Titel der in Luxemburg kotiert ist.
...nicht überteuerter IPO ist besser als umgekehrt
Peter Friedli nimmt Stellung zum Börsengang:
In der Portfoliobewertung von New Venturetec wurde der Wert der Osirisbeteiligung um 3 Millionen US$ nach unten korrigiert. Hast also Recht gehabt mit deiner Vermutung Hans, dass die Beteiligung zum realen Wert in den Büchern geführt wird. In dem Fall wird es wohl keine Höherbewertung des inneren Werts von NEV geben, ausser die Aktie legt an der Nasdaq massiv zu. :oops:
...bleibt zu hoffen, dass der Flug von Osiris anhält...
....Animatrix - Final Flight of the Osiris
Der Kommentar von Bellavista wurde ignoriert. Um die Kommentare von Bellavista wieder zu sehen, klicken Sie folgenden Link:
Nach den obigen Ausführungen hätte der Kurs der Aktie nach Euren Berechnungen massiv ansteigen müssen. Nun ist eher das Gegenteil der Fall. Was für eine Erklärung gibts dafür.?
..Kurs wurde im Vorfeld des OSIRIS IPO gepuscht und nachdem dann allen klar war dass da kein schneller Stutz zu machen ist, sind sie wieder ausgestiegen, Kurs down
..vielleicht holt NEV ja auch nur Luft für einen neuen Ausbruch..
Ich denke man sollte die einfach liegen lassen, die kommen schon wieder. Aktuell notiert der Kurs auf alle Fälle ziemlich unter dem inneren Wert. Wobei ich mir ehrlich gesagt auch mehr vom IPO von Osiris erhofft habe, aber bei Basilea war es eine Zeit lang ähnlich, die sind nach dem IPO auch gefallen und nachher massiv gestiegen, das hat den Kurs von New Venturetec anschliessend massiv nach oben gezogen, vor anderhalb Jahren lag der Kurs von NEV bei ca. Fr. 13.- und dann sind sie dieses Jahr bis auf 36.- gestiegen.
Adult stem cell biotechs: better prospects, less controversy
Several outfits are in the advanced stages of testing adult stem cells to help repair damaged bones as well as heart and breast tissue.,
By Aaron Smith, CNNMoney.com staff writer
August 9 2006: 3:37 PM EDT
NEW YORK (CNNMoney.com) -- Embryonic stem cells might hold the secrets to curing paralysis and brain damage, but they've also garnered plenty of controversy with the anti-abortion lobby because they're harvested from embryos.
However, work using adult stem cells - which are donated by grown men and women - is not only free of such controversy, it's actually much closer to getting effective products on the market.
The adult stem cell research at several biotech outfits in particular - Osiris, Cytori, Aastrom - is worth keeping an eye on according to analysts.
"From a Wall Street perspective, adult stem cells are a much better investment," said Stephen Dunn of Dawson James Securities. "These are the guys who are going to be in the news in 2007 and 2008."
President Bush recently vetoed a bill that would loosen federal restrictions on funding for embryonic stem cells, and some analysts fear that as a result the best developments in this area will be made overseas.
But work with adult stem cells isn't being held back by funding restraints and political opposition, analysts say.
"Embryonic stem cell research hasn't kept up pace with adult stem cell research," said Dunn. "Adult stem cell research is advancing so far you might not need embryonic stem cells. If the federal government is reluctant to put their money into it, then Wall Street is as well."
So while embryonic stem cell researchers are experimenting with rats , adult stem cell researchers have moved on to more advanced tests with humans. The embryonic-based stem cell treatments are probably a decade away, but the U.S. market could see its first adult-based stem cell treatments within the next couple of years.
Osiris Therapeutics (down $0.08 to $10.93, Charts ), a Baltimore-based biotech, recently raised $38.5 million via its Aug.4 IPO. The company already has a stem cell-based product on the market called Osteocel, which spurs growth in damaged bones. But the company has had a hard time finding enough donors of bone tissue to build up its inventory.
Osiris is also working on other products, including Prochymal, a treatment for a life-threatening affliction called Acute Graft versus Host Disease. This disease affects half of all patients who receive a bone marrow transplant for anemia and other diseases, and attacks the gastrointestinal tract, skin and liver.
"I like Osiris' Graft versus Host product," said Stephan Brozak, analyst for WBB Securities. "You've got a terrible disease, where Osiris has used [its product] with remarkable results."
The company just began phase 3 of clinical trials for Prochymal, which is the latest stage of testing before submission to the FDA, but it could be ready for submission in 2007. This same drug is in phase 2 testing as a treatment for Crohn's disease, a painful inflammation of the bowel.
The biotech is also in earlier stages of testing for Provacel, which would use stem cells to rebuild heart tissue following a heart attack, and for Chondrogen, which may rebuild knee cartilage.
Aastrom Biosciences (down $0.01 to $1.20, Charts ), a biotech based in Ann Arbor, is also developing products with adult stem cells to help regrow bone tissue. The company is conducting clinical trials on stem cell-based healing of long bone fractures and jaw bone reconstruction.
Dunn is bullish on Aastrom's "low-risk" trials, rating the company a "buy," with a 12-month price target of $3.75.
The San Diego biotech Cytori Therapeutics (up $0.11 to $5.80, Charts ) uses stem cells from fat -- which is extracted through a one-hour liposuction procedure using the company's Celution technology - to rebuild damaged tissue.
"Fat tissue is the richest source of stem cells," said Cytori chief executive Chris Calhoun, who hopes to submit Celutionto the FDA in 2007.
Unlike Osiris, Cytori does not use donors, but instead extracts stem cells from the patient, then processes them in the Celution device and re-injects them into the patient.
Celution is being tested in human patients in Japan who have had a single-breast mastectomy to see if the stem cell-based technology can rebuild damaged breast tissue. If successful, Celution would be used in place of silicone implants, the current treatment for rebuilding breasts.
Celution is also being tested to improve heart function in patients with severe coronary artery disease.
"We're salvaging that part of the heart that would otherwise go on to die," said CEO Calhoun, who hopes to file this treatment with the FDA in 2008.
But these tests are less advanced, and the test subjects are pigs, not humans.
Analysts are reluctant to estimate when any of these adult stem-cell treatments will come to market, or how much they'll garner in sales. With stem cells, the FDA is encountering a relatively new type of science, so the regulatory process might not be even less predictable than it is with the more traditional type of medical devices and drugs.
"The FDA is engaging in a learning process," said WBB Securities' Brozak, and that will introduce new variables into the agency's review process.
The analysts interviewed for this story do not own stock in the companies mentioned here, but Dawson James Securities conduct banking for Aastrom.
Demnext gibt's Bewegung...
Osiris Therapeutics to Present at UBS Global Life Sciences
BALTIMORE, Maryland – September 15, 2006 – Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the
inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, will be presenting at the UBS Global Life Sciences Conference in New York City on September 25, 2006.
The presentation is scheduled for 1:00 PM (Eastern Time). A live web cast may be accessed through the Company’s website at www.Osiris.com. The presentation will be archived on the Osiris website for a limited time,
under the Investors tab, beginning approximately three hours after the presentation.
Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently
markets and sells Osteocel® for regenerating bone in orthopedic indications. Prochymal™ is in Phase 3 clinical trials and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track
product. The Company’s pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen™ for regenerating cartilage in the knee, and Provacel™, for repairing heart tissue following a heart attack. Osiris is a fully integrated company, having developed stem cell capabilities in research and development, manufacturing, marketing and distribution. Osiris has developed an extensive intellectual property portfolio to
protect the company’s technology in the United States and a number of foreign countries including 45 U.S. and 163 foreign patents owned or licensed. (OSIR-G)
Forward Looking Statements
This press release may contain forward-looking statements. These forward- looking statements may generally be identified by the use of the words "may," "will," "expects," "anticipates," "believes," "estimates," and similar expressions, and involve a number of risks and uncertainties. For a variety of reasons, actual results may differ materially from those described in or contemplated by any such forward-looking statement. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject.
Bis jetzt noch nichts passiert. Kommts noch, oder ist deine Einschätzung zu optimistisch?
..also explodieren wird hier nix
..soviel ich weiss, hat P. Friedli gut Kontakte zur UBS...und das wird sicher was bringen..schaun wir mal..was das kommt...
Bis jetzt noch nichts passiert. Kommts noch, oder ist deine Einschätzung zu optimistisch?
Osiris, Freitag letzter Trade 153'626 (29.09.)
Viel los war ja nicht am Freitag und dann am Schluss dieser Taucher mit hohem Volumen ist schon nicht das, was man sich wünschen würde.
Heute gibt nev jedenfalls schon ziemlich nach.
Von Ecen sollte es ja nicht herrühren. Also ist osiris als Auslöser ziemlich naheliegend.
Der Kommentar von nummelin wurde ignoriert. Um die Kommentare von nummelin wieder zu sehen, klicken Sie folgenden Link:
Bin mal eingestiegen einen kleinen Zock wert...
One day you lose,and another day another win!!
© 1998-2021 / cash
| Impressum |